Analyst Expectations for Esperion Therapeutics's Future
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 5 analysts have published their opinion on Esperion Therapeutics (NASDAQ:ESPR) stock, with an average price target of $14.0, implying significant upside from the current price of $1.33. The current average has increased by 111.48% from the previous average price target of $6.62.
June 26, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Esperion Therapeutics (NASDAQ:ESPR) has received 5 bullish analyst ratings in the past 3 months, with an average price target of $14.0, indicating a significant upside from the current price of $1.33.
The 5 analysts covering Esperion Therapeutics have all given bullish ratings, with an average price target of $14.0, which is significantly higher than the current price of $1.33. This indicates that they believe the stock has the potential to increase in value in the short term. The increase in the average price target by 111.48% from the previous average also shows growing confidence in the stock's potential.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100